Pharming (PHAR) Gross Margin (2020 - 2026)
Pharming's (PHAR) quarterly Gross Margin came in at 86.97% in Q2 2026, down 8996306191.0% YoY from N/an in Q2 2025, and down 4.25% on a QoQ basis from 90.83% in Q1 2026.
Pharming (PHAR) Gross Margin (2020 - 2026) Analysis & Trends
Pharming (PHAR) has 7 years of Gross Margin data on file, last reported at 86.97% in Q2 2026.
- Quarterly Gross Margin fell 8996306191.0% year-over-year to 86.97% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 86.52% (down 22921981363.0% YoY) and the FY2025 annual result came in at 87.9%, down 19.0% from the prior year.
- Gross Margin declined to 86.97% in Q2 2026, from 90.83% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 179802955665024.62% in Q4 2023 to a low of 0.0% in Q1 2025.
- A 5-year average of 14914355181225.08% and a median of 90.63% in 2023 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2023 — Gross Margin soared 2000000000 bps — and 2024, when it tumbled 2000000000 bps.
- Tracing PHAR's Gross Margin over 5 years: stood at 92.52% in 2022, then soared by 2000000000 bps to 179802955665024.62% in 2023, then slumped by 51 bps to 88655256723716.38% in 2024, then slumped by 100 bps to 80.19% in 2025, then gained by 8 bps to 86.97% in 2026.
- The last three Gross Margin figures came in at 86.97% (Q2 2026), 90.83% (Q1 2026), and 80.19% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | 86.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 86.97% |
| Mar 31, 2026 | 90.83% |
| Dec 31, 2025 | 80.19% |
| Sep 30, 2025 | 92.70% |
| Jun 30, 2025 | 89,963,148.88% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2024 | 88,655,256,723,716.39% |
| Sep 30, 2024 | 90,909,090.91% |
| Jun 30, 2024 | 87.38% |
| Mar 31, 2024 | 84.91% |
| Dec 31, 2023 | 179,802,955,665,024.62% |
| Sep 30, 2023 | 87.56% |
| Jun 30, 2023 | 0.00% |
| Mar 31, 2023 | 90.42% |
| Dec 31, 2022 | 92.52% |
| Sep 30, 2022 | 95.76% |
| Jun 30, 2022 | 92.02% |
| Mar 31, 2022 | 89.48% |
| Dec 31, 2021 | -60.16% |
| Sep 30, 2021 | 88.64% |